Selling More For Less In China Pays Off For AstraZeneca
Volume gains from the entry into China’s national reimbursement program offset deep price cut for AstraZeneca’s major selling Tagrisso in the second quarter of 2021.
You may also be interested in...
Any delays caused by unpredictable regulatory reviews related to the export of genetic materials threaten to derail the inclusion of China in international clinical trials, caution two trade groups representing the pharma industry in the country.
Everest Medicines’ deal with Canadian biotech Providence Therapeutics contains a full transfer of technology which may be appealing to Chinese regulators.
One initial public offering and six private funding deals add a total of $357m into the biotech funding pot in China as multiple new ventures look to progress pipeline assets and build capabilities.